Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage

Clinical Chemistry

Volumn 48, Issue 2, 2002, Pages 261-268

  Ferré, Natàlia ^a   Camps, Jordi ^a   Prats, Eduard ^a   Vilella, Elisabet ^a   Paul, Antoni ^a   Figuera, Lídia ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; PARAOXON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG HYDROLYSIS; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 0036151042     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.2.261     Document Type: Article

References (43)

1. Human serum paraoxonase/arylesterase
2. Structural and functional diversity of paraoxonases
3. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family
4. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation
5. High density lipoprotein and lipoprotein oxidation
6. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
7. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
8. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation
9. HDL, its enzymes and its potential to influence lipid peroxidation
10. The Yin and Yang of oxidation in the development of fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture
11. HDL apolipoprotein A-1 attenuates oxidative modification of low density lipoprotein: Studies in transgenic mice
12. Apolipoprotein J is associated with paraoxonase in human plasma
13. Two alleles of the human paraoxonase gene produce different amounts of mRNA
14. Human liver paraoxonase (PON1): Subcellular distribution and characterization
15. Serum arylesterase isoenzymes in chronic hepatitis
16. Characteristics and behaviour of arylesterase in human serum and liver
17. Improved specific assay for serum arylesterase using a water-soluble substrate
18. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase
19. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme
20. The human serum paraoxonase/arylesterase polymorphism
21. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure
22. The molecular basis of the human serum paraoxonase activity polymorphism
23. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine
24. Toward a checklist for reporting studies of diagnostic accuracy of medical tests
25. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
26. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
27. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites
28. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism
29. Human serum paraoxonases (PON1) Gln and Arg selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions
30. Partial purification of paraoxonase from rat liver
31. Rat liver paraoxonase: Subcellular distribution and characterization
32. Differences in the kinetic properties, effect of calcium and sensitivity to inhibitors of paraoxon hydrolase activity in rat plasma and microsomal fraction from rat liver
33. Divergent effects of classical inducers on rat plasma and microsomal fraction paraoxonase and arylesterase
34. Purification and characterization of paraoxon hydrolase from rat liver
35. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials
36. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
37. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis
38. Abnormal plasma lipoproteins and lecithin-cholesterol acyltransferase deficiency in alcoholic liver disease
39. Targeted disruption of the murine lecithin: Cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration
40. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
41. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
42. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
43. Assessment of liver function